US 9,000,030 B2 · Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors

Abstract

A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

Claims4

Dependent claims

A method for inhibiting neuronal damage comprising administering to a person in need thereof an effective amount of a compound of the formula:

wherein R2 is β-OH and R1, R3, R4, and R5 are H.

Dependencies are inferred from the claim text.

Facts

Application

13/673,479Filed 9 Nov 2012 · continuation

Priority

10 Feb 2009

Published

US 2013/0165495 A127 Jun 2013

Granted

7 Apr 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/047
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates: having two or more hydroxy groups, e.g. sorbitol
A61K 31/045
Medicinal preparations containing organic active ingredients: hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
A61K 31/122
Ketones: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/215
Esters, e.g. nitroglycerine, selenocyanates: of carboxylic acids

Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors

Life of this patent

Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors

Life of this patent

Abstract

Claims4